Hyperuricemia predicted adverse outcomes in very elderly patients with non-valvular atrial fibrillation

Objective Elevated serum uric acid predicts poor outcomes in patients with cardiovascular disease.We aimed to examine associations between hyperuricemia and clinical outcomes among very elderly patients with non-valvular atrial fibrillation(NVAF).Methods Elderly patients(≥80 years)with NVAF admitted to our hospital from January 2009 to December 2015 were retrospectively studied and were followed up until April 2017.

新型口服抗凝药在老年非瓣膜性房颤患者中的临床应用

目的探讨传统口服抗凝药华法林和新型口服抗凝药利伐沙班在老年非瓣膜性心房颤动(房颤)患者中的安全性。方法 90例房颤患者,按药物应用类型分为常规组和新型组,每组45例。两组患者均给予基础治疗,常规组采用口服华法林治疗,新型组采用口服利伐沙班治疗。观察比较两组患者的栓塞事件、出血事件发生情况。结果新型组患者的栓塞事件发生率4.44%(2/45)和出血事件发生率0(0/45)均明显低于常规组的22.22%(10/45)、8.89%(4/45),差异具有统计学意义(P<0.05)。结论新型口服抗凝药利伐沙班在老年非瓣膜性房颤患者中的应用效果显著,不良反应发生率更低,值得临床推广。

房颤合并冠心病老年患者抗栓治疗方案的循证实践

目的针对近期收治的1例房颤合并冠心病患者抗栓治疗方案的选择,检索当前最佳证据,为临床合理治疗提供依据。方法全面检索Pub Med、MEDLINE(Ovid)、EMbase、h e Cochrane Library(2014年第5期),检索时限截至2014年5月。查找与房颤合并冠心病患者抗栓治疗有关的证据,对所获证据进行分析评价后,为患者制定抗检治疗方案。结果现有证据表明,目前尚无明确的房颤合并稳定性冠心病老年患者抗栓治疗的最佳方案。结论正确评价血栓风险与出血风险,是房颤合并冠心病老年患者抗栓治疗获益的关键。